or Try an Advanced Search...

    Technical Analysis for REPL - Replimune Group, Inc.

    Grade Last Price % Change Price Change
    F 6.33 -1.40% -0.09
    REPL closed down 1.4 percent on Wednesday, April 24, 2024, on 55 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 16
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical REPL trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Oversold Stochastic Weakness 0.00%
    Oversold Stochastic Weakness -1.40%
    New 52 Week Closing Low Bearish -1.40%
    Lower Bollinger Band Walk Weakness -1.40%
    Down 3 Days in a Row Weakness -1.40%
    Lower Bollinger Band Touch Weakness -1.40%
    Oversold Stochastic Weakness -1.40%
    New 52 Week Closing Low Bearish -1.86%
    Expansion Breakdown Bearish Swing Setup -1.86%
    Older End-of-Day Signals for REPL ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 7 hours ago
    Up 2% about 7 hours ago
    Lower Bollinger Band Support about 10 hours ago
    60 Minute Opening Range Breakdown about 10 hours ago
    Down 3% about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    REPL Chart by TradingView
    Basic chart:

    Profile

    Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1

    Is REPL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 7 Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
    Apr 4 Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Mar 26 Replimune Group announces CEO transition
    Mar 26 Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
    Mar 11 How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
    Mar 8 What Makes Replimune Group, Inc. (REPL) a New Buy Stock
    Mar 6 Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
    Mar 5 Replimune to Present at Three Upcoming Investor Conferences
    Feb 27 12 Best Medical Stocks to Buy Under $10
    Feb 23 Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
    See more REPL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 24.81
    52 Week Low 5.9
    Average Volume 1,155,226
    200-Day Moving Average 12.43
    50-Day Moving Average 7.85
    20-Day Moving Average 7.14
    10-Day Moving Average 6.84
    Average True Range 0.44
    RSI (14) 30.07
    ADX 31.82
    +DI 12.14
    -DI 32.64
    Chandelier Exit (Long, 3 ATRs) 7.14
    Chandelier Exit (Short, 3 ATRs) 7.52
    Upper Bollinger Bands 8.14
    Lower Bollinger Band 6.14
    Percent B (%b) 0.09
    BandWidth 27.99
    MACD Line -0.42
    MACD Signal Line -0.35
    MACD Histogram -0.065
    Fundamentals Value
    Market Cap 388.58 Million
    Num Shares 61.4 Million
    EPS -3.16
    Price-to-Earnings (P/E) Ratio -2.00
    Price-to-Sales 0.00
    Price-to-Book 1.13
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.02
    Resistance 3 (R3) 7.05 6.86 6.91
    Resistance 2 (R2) 6.86 6.68 6.84 6.87
    Resistance 1 (R1) 6.59 6.57 6.50 6.56 6.83
    Pivot Point 6.40 6.40 6.35 6.38 6.40
    Support 1 (S1) 6.13 6.22 6.04 6.10 5.83
    Support 2 (S2) 5.94 6.11 5.92 5.79
    Support 3 (S3) 5.67 5.94 5.76
    Support 4 (S4) 5.64